{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:44:18Z","timestamp":1777034658458,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.surg.2019.05.010","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:44:49Z","timestamp":1562028289000},"page":"277-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery"],"prefix":"10.1016","volume":"166","author":[{"given":"Chad A.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana I.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Aldakkak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kulwinder","family":"Dua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Callisia N.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parag","family":"Tolat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas B.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen K.","family":"Christians","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2019.05.010_bib1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1245\/ASO.2006.08.011","article-title":"Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy","volume":"13","author":"Varadhachary","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib2","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1245\/s10434-009-0409-5","article-title":"AHPBA\/SSO\/SSAT Consensus Conference on Resectable and borderline resectable pancreatic cancer: Rationale and overview of the conference","volume":"16","author":"Vauthey","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib3","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","article-title":"Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement","volume":"16","author":"Callery","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib4","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-013-2886-9","article-title":"Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design","volume":"20","author":"Katz","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib5","doi-asserted-by":"crossref","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.surg.2019.05.010_bib6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","article-title":"Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)","volume":"155","author":"Bockhorn","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2019.05.010_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","article-title":"EMT and dissemination precede pancreatic tumor formation","volume":"148","author":"Rhim","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.surg.2019.05.010_bib8","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nature09515","article-title":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","volume":"467","author":"Yachida","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.surg.2019.05.010_bib9","series-title":"Pancreatic Adenocarcinoma, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)","year":"2017"},{"key":"10.1016\/j.surg.2019.05.010_bib10","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1245\/s10434-009-0413-9","article-title":"Combined modality treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement","volume":"16","author":"Abrams","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib11","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1245\/s10434-009-0416-6","article-title":"Surgical treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement","volume":"16","author":"Evans","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/SLA.0000000000002957","article-title":"A\u00a0phase II clinical trial of molecular profiled neoadjuvant therapy for localized pancreatic ductal adenocarcinoma","volume":"268","author":"Tsai","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2019.05.010_bib13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","article-title":"Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX","volume":"269","author":"Michelakos","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2019.05.010_bib14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.surg.2015.09.018","article-title":"Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy","volume":"159","author":"Christians","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2019.05.010_bib15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1200\/JOP.2016.016162","article-title":"Multimodality therapy in patients with borderline resectable or locally advanced pancreatic cancer: Importance of locoregional therapies for a systemic disease","volume":"12","author":"Tsai","year":"2016","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.surg.2019.05.010_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.surg.2019.05.010_bib17","series-title":"Mastery of Surgery","article-title":"Pancreaticoduodenectomy and total pancreatectomy for cancer","author":"Evans","year":"2018"},{"key":"10.1016\/j.surg.2019.05.010_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/jso.23166","article-title":"Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma","volume":"107","author":"Christians","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib19","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.suc.2016.07.005","article-title":"Techniques of vascular resection and reconstruction in pancreatic cancer","volume":"96","author":"Younan","year":"2016","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.surg.2019.05.010_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2019.05.010_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pan.2015.11.007","article-title":"Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages","volume":"16","author":"Tang","year":"2016","journal-title":"Pancreatol"},{"key":"10.1016\/j.surg.2019.05.010_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2019.05.010_bib23","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.surg.2017.09.012","article-title":"Locally advanced pancreas cancer: Staging and goals of therapy","volume":"163","author":"Chatzizacharias","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2019.05.010_bib24","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/SLA.0000000000000968","article-title":"The impact of neural invasion severity in gastrointestinal malignancies: A clinicopathological study","volume":"260","author":"Liebl","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2019.05.010_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.suronc.2017.01.007","article-title":"The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis","volume":"26","author":"Schorn","year":"2017","journal-title":"Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1096-9098(199707)65:3<164::AID-JSO4>3.0.CO;2-4","article-title":"Perineural invasion by ductal adenocarcinoma of the pancreas","volume":"65","author":"Takahashi","year":"1997","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/PAS.0b013e31824104c5","article-title":"Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma","volume":"36","author":"Chatterjee","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.surg.2019.05.010_bib28","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2019.05.010_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jnci\/djp456","article-title":"Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves","volume":"102","author":"Gil","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.surg.2019.05.010_bib30","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1002\/cncr.24396","article-title":"Perineural invasion in cancer: A review of the literature","volume":"115","author":"Liebig","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2019.05.010_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: A prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2019.05.010_bib32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/jso.25004","article-title":"Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma","volume":"117","author":"Chapman","year":"2018","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib33","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/hpb.12448","article-title":"Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer","volume":"17","author":"Aldakkak","year":"2015","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.surg.2019.05.010_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jamcollsurg.2016.02.009","article-title":"Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: A National Cancer database study","volume":"223","author":"Bergquist","year":"2016","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.surg.2019.05.010_bib35","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1245\/s10434-012-2809-1","article-title":"CA19-9 in potentially resectable pancreatic cancer: Perspective to adjust surgical and perioperative therapy","volume":"20","author":"Hartwig","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdr561","article-title":"The prognostic and predictive value of serum CA19.9 in pancreatic cancer","volume":"23","author":"Humphris","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib37","unstructured":"Tsai S, George B, Wittmann D, et\u00a0al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg. [Epub ahead of print]"},{"key":"10.1016\/j.surg.2019.05.010_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.molonc.2016.01.006","article-title":"Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer","volume":"10","author":"Riva","year":"2016","journal-title":"Mol Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.surg.2019.05.010_bib40","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.surg.2019.05.010_bib41","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1245\/s10434-015-4649-2","article-title":"Non-metastatic pancreatic cancer: Resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy","volume":"22","author":"Evans","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2019.05.010_bib42","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamasurg.2016.1113","article-title":"Therapeutic advances in localized pancreatic cancer","volume":"151","author":"Tsai","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.surg.2019.05.010_bib43","unstructured":"Truty MJ, Kendrick ML, Nagorney DM, et\u00a0al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer. Ann Surg. [Epub ahead of print]"},{"key":"10.1016\/j.surg.2019.05.010_bib44","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.surg.2019.05.010_bib45","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.gassur.2006.08.018","article-title":"1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience","volume":"10","author":"Winter","year":"2006","journal-title":"J\u00a0Gastrointest Surg"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606019302508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606019302508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:51:44Z","timestamp":1758538304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606019302508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0039606019302508"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2019.05.010","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2019.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}